Medannex unveils First-in-Human study of novel cancer therapy at ASCO 2024

Released: Saturday 1st June 2024

Medannex Ltd (Edinburgh) today revealed details of the ATTAINMENT study at the American Society of Clinical Oncology (ASCO) Annual Meeting.


The Phase 1b oncology study is the first clinical evaluation of a therapy targeting annexin-A1, a new and unique cancer target.


Full details here:


View all News